Back to Top Skip to main content

HPV vaccine now recommended for those up to age 45

https://www.nfid.org/infectious-diseases/hpv/ Recent CDC and FDA guidance recommends that men and women up to 45 years of age get vaccinated to protect against the Human papillomavirus (HPV). HPV is the most common sexually transmitted infection and can cause certain cancers and genital warts. More than 14 million new HPV infections occur in the U.S. each year, and about 80 percent of sexually active men and women are infected with HPV at some point in their lives. (National Foundation for Infectious Diseases image) Recent CDC and FDA guidance recommends that men and women up to 45 years of age get vaccinated to protect against the Human papillomavirus (HPV). HPV is the most common sexually transmitted infection and can cause certain cancers and genital warts. More than 14 million new HPV infections occur in the U.S. each year, and about 80 percent of sexually active men and women are infected with HPV at some point in their lives. (National Foundation for Infectious Diseases image)

Recommended Content:

Conditions and Treatments | Health Readiness | Preventive Health | Men's Health | Women's Health | Immunization Healthcare | Vaccine-Preventable Diseases | Vaccine Recommendations

The Food and Drug Administration has raised the recommended age to receive the vaccine for human papillomavirus, or HPV to 45. Health care experts say that's good news for women and men who did not receive the anti-cancer vaccine in childhood.

"There are hundreds of different strains of HPV," said Navy Cmdr. Shannon Lamb, a urogynecologist and the U.S. Navy Bureau of Medicine and Surgery's Women's Health Branch chief. "The vaccine doesn't protect from all of them, but it does protect from the most common ones that cause different types of cancers as well as genital warts."

HPV spreads through intimate skin-on-skin contact. Typically, the vaccine is recommended for girls and boys as young as age 9, and women and men up to age 26.

“It's recommended for young people so they're protected before they're ever exposed to the virus," Lamb said. "HPV is a very common infection. Over 80 percent of people will be infected in their lifetime."

In 2018, the FDA approved the vaccine for women and men up to age 45. While many adults have been exposed to some strains of HPV, most have not been exposed to all nine types covered by the vaccine.

"Therefore, expanding the age range for vaccination can help prevent HPV-related diseases in more individuals," she said.

Usually, people don't exhibit any signs or symptoms of an HPV infection, and most won't develop health problems related to HPV. The virus typically goes away on its own after a couple of years. But there's no way to predict who will clear the virus and who won't. And for those who don't, the consequences can be deadly.

According to the Centers for Disease Control and Prevention, HPV is responsible for more than 90 percent of all cervical and anal cancers, 70 percent of vaginal and vulvar cancers, and more than 60 percent of penile cancers. Every year, approximately 25,000 women and 19,000 men are affected by cancers caused by HPV.

For HPV vaccination of service members, the Department of Defense follows guidelines published by the Advisory Committee on Immunization Practices. Lamb says the vaccine isn't mandatory, but it's strongly recommended.

"The vaccine creates a lot of benefit for men and women," Lamb said, "and we know it works." The number of cases of genital warts in the United States has dramatically declined in the military as well as civilian populations since the vaccine was introduced, she said.

"The HPV vaccine is definitely making an impact," Lamb said. "But we're still missing a good chunk of the population that could benefit."

The vaccine is administered as a two-dose series for those under age 15, and a three-dose series for older people. According to data from the Armed Forces Health Surveillance Branch's Medical Surveillance Monthly Report, only 26.6 percent of eligible servicewomen ages 17-26 initiated the vaccine during 2007-2017. During the same time period, only 5.8 percent of eligible servicemen in the same age group did so.

Further, for those who did initiate the vaccine and then remained in service for at least six months, only 46.6 percent of servicewomen and 35.1 percent of servicemen completed the recommended three doses.

"I think there's a lot of misinformation about the HPV vaccine," Lamb said. "Parents may think their kids don’t need it because they're not yet sexually active, for example, and older people may not understand they may be at risk."

Lamb is hopeful that with awareness people will make it a priority to talk to their health care providers about their risk for new HPV infections and the possible benefits of vaccination.

She notes that cancers caused by HPV may take years to develop after a person contracts the virus. Further, while there are cervical HPV screening tests available for women for high risk strains, there are no routine screening tests for men or tests that include all strains of HPV. Over 12,000 women living in the United States will be diagnosed with cervical cancer, and over 4,000 women die from cervical cancer annually. Women at highest risk are those who don’t undergo recommended screening and are not vaccinated, as well as women who smoke or have lowered immune systems.

TRICARE covers the HPV vaccine as recommended by the CDC. More information about the HPV vaccine can be found on the TRICARE website.

You also may be interested in...

DHA IPM 19-006: 2019–2020 Seasonal Influenza Vaccination Program (IVP)

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (o), implementing instructions, assigns responsibilities, and prescribes procedures for the seasonal influenza vaccination program. • This DHA-IPM cancels and reissues DHA-IPM 18-005. • This DHA-IPM is effective immediately and will expire 12 months from the date of issue.

DODI 6205.02 DOD Immunization Program

Policy

Establishes policy, assigns responsibilities, and provides procedures to establish a uniform DoD immunization program, in accordance with the authority in DoDD 6200.04 and DoD Instruction (DoDI) 1010.10.

DHA PI 6200.02: Comprehensive Contraceptive Counseling and Access to the Full Range of Methods of Contraception

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), in accordance with the requirements of References (c) through (i), and the guidance of References (j) through (v), establishes the Defense Health Agency’s (DHA) procedures for comprehensive standards on healthcare with respect to access to comprehensive contraceptive counseling and the full range of contraceptive methods for members of the Armed Forces and all eligible beneficiaries of the Military Health System (MHS).

  • Identification #: 6200.02
  • Date: 5/13/2019
  • Type: DHA Procedural Instruction
  • Topics: Women's Health

DHA IPM 19-003: Reserve Health Readiness Program

Policy

This Defense Health Agency-Interim Procedures Memorandum (DHA-IPM), based on the authority of References (a) through (c), and in accordance with the guidance of References (d) through (i): • Provides utilization guidance and funding requirements for the RHRP contract to supplement Reserve Component Individual Medical Readiness (IMR) and Deployment Health activities when Service organic health readiness resources are not available to meet mission requirements. • Provides utilization guidance and funding requirements for the RHRP contract for Active Duty enrolled in TRICARE Prime Remote, U.S. Coast Guard (USCG), USCG Reserves, and re-deploying DoD civilians (e.g., U.S. Army Corps of Engineers and U.S. Army Intelligence and Security Command). • Communicate procedure guidance to all DoD organizations utilizing RHRP services. • Will expire effective 12 months from the date of issue and be converted to a DHA-Procedural Instruction.

  • Identification #: 19-003
  • Date: 3/8/2019
  • Type: DHA Interim Procedures Memorandum
  • Topics: Health Readiness

III MEF Force Health Protection Requirements 2019

Policy

DHA PI 6025.14: Active Duty Service Member (ADSM) Erythrocyte Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency and Sickle Cell Trait (SCT) Screening

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (o), establishes Defense Health Agency’s (DHA) procedures to implement Reference (d), for erythrocyte G6PD deficiency and SCT screening at the appropriate points: during entry to the Military Services (at appointment, enlistment, or induction (Reference (j)), at pre-deployment, and at other points as indicated for validation of results (per References (k), (m), and (n)).

MILPERSMAN 1730-020 Immunization Exemptions for Religious Beliefs

Policy

Process for requesting immunization exemptions, pursuant to the Navy Military Personnel Manual.

DHA PI 6025.07: Naloxone in the MTFs

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) through (c), and in accordance with the guidance of References (d) through (h), establishes the Defense Health Agency’s (DHA) procedures for prescribing and dispensing naloxone by pharmacists in MTFs to eligible beneficiaries, upon beneficiary request, or when the pharmacist determines the beneficiary meets the established criteria for being at risk for a life-threatening opiate overdose.

DHA PI 6200.05: Force Health Protection Quality Assurance (FHPQA) Program

Policy

This Defense Health Agency-Procedural Instruction (DHA-PI), based on the authority of References (a) and (b), and in accordance with the guidance of References (c) through (ab), establishes the procedures for the FHPQA Program as defined in Reference (z). This DHA-PI applies to: a. OSD, the Military Departments (including the United States Coast Guard (USCG) at all times, including when it is a Service in the Department of Homeland Security by agreement with that Department), the Office of the Chairman of the Joint Chiefs of Staff (CJCS) and the Joint Staff, the Combatant Commands, the Office of the Inspector General of the DoD, the Defense Agencies, the DoD Field Activities, and all other organizational entities within the DoD (referred to collectively in this DHA-PI as the “DoD Components”). b. Civilian personnel, as defined in Reference (e), and DoD contractor personnel authorized to accompany the force (CAAF), in accordance with References (j), (m), and (n), respectively.

  • Identification #: DHA PI 6200.05
  • Date: 5/2/2018
  • Type: DHA Procedural Instruction
  • Topics: Health Readiness

Interim Guidance for Prevention of Sexual Transmission of Zika Virus

Policy

With this update, CDC is expanding its existing recommendations to cover all pregnant couples, which includes pregnant women with female sex partners. This guidance also describes what other couples (those who are not pregnant or planning to become pregnant) can do to reduce the risk for Zika virus transmission. CDC’s recommendations for couples planning to become pregnant have been published separately (9).

DoD Instruction 6200.05: Force Health Protection Quality Assurance (FHPQA) Program

Policy

This issuance establishes policy, assigns responsibilities, and defines requirements for the development and establishment of the FHPQA Program in accordance with the authority in DoD Directive (DoDD) 5124.02, Sections 731 and 738 of Public Law 108-375; Sections 1074f, 1092a, and 1073b of Title 10, United States Code; and DoDDs 6200.04 and 5136.13.

DoD Instruction 6490.13: Comprehensive Policy on Traumatic Brain Injury-Related Neurocognitive Assessments by the Military Services

Policy

This instruction establishes policy, assigns responsibilities, and prescribes standard elements, pursuant to section 722 of Public Law 111-383, requiring the implementation of a comprehensive neurocognitive assessment policy in the Military Services.

Embedded Fragment Analyses

Policy

Clarification of the Requirement for Continuation of Semi-Annual Reporting of Results of Embedded Fragment Analyses

Pre-Deployment, Deployment, and Post-Deployment Training, Screening, and Monitoring Guidance for Department of Defense Personnel Deployed to Ebola Outbreak Areas

Policy

Department of Defense (DoD) personnel (Service members and civilian employees)deployed to Centers for Disease Control and Prevention defined Ebola outbreak areas will complete pre and post-deployment screening and training requirements outlined in this memorandum and supplemented by United States Africa Command (USAFRICOM) guidance.

Detecting and Reporting DoD Cases of Ebola Virus Disease Infection

Policy

Guidance as of 17 OCT 2014 from the Department of Defese (AFHSC)for Detecting and Reporting DoD Cases of Ebola Virus Disease Infection

<< < 1 2 3 4 > >> 
Showing results 1 - 15 Page 1 of 4

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.